Royalty Report: Drugs, Multiple Sclerosis, Cancer – Collection: 376029

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Multiple Sclerosis
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 376029

License Grant
Kesimpta is being developed and marketed worldwide by Licensee under a license agreement between Licensor of Denmark and Swiss Licensee.
License Property
Licensor used technology licensed from another party to generate the CD20 antibody forming part of Kesimpta.

Kesimpta is a human monoclonal antibody that targets an epitope on the CD20 molecule encompassing parts of the small and large extracellular loops. Kesimpta is the first B-cell therapy that can be self-administered by patients at home using the Sensoready autoinjector pen, once monthly after starting therapy.

Field of Use
Kesimpta was approved for the treatment of RMS in adults.
RMS is a form of multiple sclerosis in adults.

IPSCIO Record ID: 292649

License Grant
The Company received an exclusive, worldwide license to develop and commercialize VUMERITY.
License Property
VUMERITY is novel fumarate for the treatment of RMS (relapsing multiple sclerosis).
Field of Use
VUMERITY is a prescription medicine used to treat people with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

IPSCIO Record ID: 275366

License Grant
Licensor of Denmark grants Licensor of Switzerland. the remaining rights to ofatumumab.

The product, Ofatumumab, is being commercialized by Licensee.

License Property
The Product, ofatumumab, is marketed as Arzerra for certain indications of chronic lymphocytic leukemia (CLL).

Ofatumumab is a human IgG1k mAb that targets an epitope on the CD20 molecule, which is found on the surface of B-cells, the type of cell which is believed to trigger the inflammatory process that leads to multiple sclerosis (MS).

Field of Use
Ofatumumab for the treatment of cancer and also for non-cancer treatments.  Ofatumumab, previously approved for certain CLL indications, is in pivotal Phase III testing by Licensee for the treatment of RMS, with the Phase III ASCLEPIOS I and II studies.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.